AbbVie

Tweet this page
<
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 11 Mar 2019
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

250,000€

Financial year: Jan 2018 - Dec 2018

Lobbyists (Full time equivalent)

0.75 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

6

Lobbying Costs over the years

  • Info

    AbbVie   (ABBV)

    EU Transparency Register

    934069612666-51 First registered on 20 Jan 2014

    Goals / Remit

    AbbVie is a Specialty-focused, research-based biopharmaceutical company.

    We are approximately 30,000 people focused on developing new products and new ways to help people manage some of the most serious health conditions. We are scientists, researchers, communicators, manufacturing specialists, and regulatory experts.

    AbbVie began as the pharmaceutical leader, Abbott, which was founded in 1888 by Chicago physician, Dr. Wallace Abbott. Since then, Abbott has evolved to become a global healthcare leader, delivering innovative pharmaceutical, nutritional, diagnostic, and medical products to people in more than 150 countries.

    On January 1, 2013, AbbVie was founded, a global biopharmaceutical company with the focus and capabilities to address some of the world's greatest health challenges. AbbVie has the stability, resources, expertise, and passion to discover, develop, and bring to market groundbreaking science to solve the biggest health problems that face the world today and tomorrow.

    Main EU files targeted

    - Implementation of the regulation on Clinical Trials
    - Implementation of the legislation on Falsified Medicines
    - Joint Procurement for medical countermeasures
    - Commission expert group on safe and timely access for patients
    - Prevention and Early Intervention in Chronic Diseases
    - Demographic change and healthy ageing
    - Competition in the pharmaceutical sector
    - Pharmaceutical industrial policy including intellectual property policies
    - Revision of Medical Device and IVD Regulation
    - European Commission activities around ensuring effective, resilient and sustainable healthcare systems
    - Access to Medicines

    Address

    Head Office
    North Waukegan Road, 1
    North Chicago IL 60064
    UNITED STATES
    EU Office
    Regus Offices - offices 507-508
    Square de Meeus 37
    Brussels 1000
    BELGIUM
  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    25%3

    Lobbyists (Full time equivalent)

    0.75

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 11 Mar 2019

    Name Start date End Date
    Philip SCHWAB 07 Jun 2023 06 Jun 2024
    Christian BARACAT 22 Sep 2023 20 Sep 2024
    Janusz LINKOWSKI 20 Mar 2024 02 Oct 2024
    Mr Janusz LINKOWSKI 20 Mar 2024 15 Apr 2024
    Mr Christian Baracat 22 Sep 2023 15 Apr 2024
    Mr Felix KUBITSCHEK 22 Sep 2023 01 Feb 2024
    Mr Philip SCHWAB 07 Jun 2023 15 Apr 2024
    Mr Felix KUBITSCHEK 12 Jul 2022 12 Jul 2023
    Mr Christian Baracat 25 Jun 2022 24 Jun 2023
    Ms Jennifer SHUM 05 Feb 2016 02 Feb 2017

    Complementary Information

    While 3 persons are engaged in activities falling under the scope of the Transparency Register, each person's dedicated working time towards specific activities covered by the register does not account for 25% of their respective working time.

    Person in charge of EU relations

    Mr Ludovic Lacaine (Government Affairs Director, Brussels/EU)

    Person with legal responsibility

    Mr Richard A. Gonzalez (Chairman of the Board and Chief Executive Officer)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    - American Chamber of Commerce to the EU
    - European Federation of Pharmaceutical Industries and Association (EFPIA)
    - European Biopharmaceutical Enterprises (EBE)
    - EuropaBio – the European Association of Bio-Industries

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2018 - Dec 2018

    Lobbying costs for closed financial year

    250,000€

    Other financial info

    In order to avoid double reporting on the Register, this figure excludes trade association membership fees.

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    None

    Communication activities

    None

    Other activities

    - Raise awareness about healthy ageing and healthcare sustainability
    - Increase Europe’s competitiveness as a hub for R&D investments
    - Work towards a regulatory and Intellectual property framework that fosters innovation and improves access to patients

  • Meetings

    Meetings

    6 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard